Answers are grounded in this paper and cite their sources.
Cohort study reveals progressive choroid plexus enlargement in secondary progressive multiple sclerosis, indicating its potential as an inflammatory biomarker for neurodegeneration.
BACKGROUND: The choroid plexus (CP) is increasingly recognised as a contributor to chronic inflammation in multiple sclerosis (MS). While CP enlargement is reported in early MS, its role in secondary progressive MS (SPMS) is poorly understood. We aimed to quantify CP volume in SPMS and compare it to relapsing-remitting MS (RRMS) and clinically isolated syndrome (CIS), and to assess associations with disease severity and progression. METHODS: CP volumes were manually segmented and normalised to intracranial volume in 121 MS patients (32 CIS, 49 RRMS, 39 SPMS). Age correction was applied using a healthy control cohort (n = 109). Cross-sectional and longitudinal analyses were performed to assess associations between baseline CP volume, ventricular size, lesion burden, and brain atrophy. RESULTS: CP volume increased significantly across MS phenotypes: SPMS patients showed 32 % higher CP volume than CIS (p < 0.001) and 25 % higher than RRMS (p < 0.001). CP enlargement in SPMS was independent of ventricular size, indicating distinct underlying mechanisms. While lesion burden was the primary determinant of brain atrophy in SPMS, longitudinal data revealed significant associations of baseline CP volume with chronic lesion expansion (r²=0.33) and brain volume loss (r²=0.51). CONCLUSION: CP enlargement is a progressive feature of MS, not driven by ventricular expansion. In SPMS, it may reflect ongoing inflammation contributing to tissue damage, supporting its role as a biomarker.
No takes yet. Share an insight, caveat, or question.
Klistorner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: